BELLEVUE, WA / ACCESS Newswire / April 9, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) ("OSR Holdings" or the "Company") today announced a strategic transaction for capital structure optimization with ...
Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further investigation of VXM01 The reported safety ...
BELLEVUE, WA / ACCESS Newswire / April 9, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) ("OSR Holdings" or the "Company") today announced a strategic transaction for capital structure optimization with Whit ...
The reported safety and tolerability data, together with early indications for the potential relevance of a VXM01dependent, VEGFR-2 specific immune response in GBM therapy warrant further study. VXM01 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results